Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: To determine the safety and efficacy of gemcitabine and cisplatin in patients with taxane resistant metastatic breast cancer. Patients and methods: Thirty-three taxane resistant metastatic breast cancer patients were treated with gemcitabine 1,250 mg/m2 IV infusion over 30 min on days 1 and 8, and with cisplatin 75 mg/m2 by IV infusion over 1 h on day 1 in 21 day cycles. Results: Of the 30 evaluable patients, there were 9 (30%) partial responses and no complete response, an overall objective response rate of 30%. Median time to progression and median survival duration for all study subjects were 7 (95% CI 5.1-8.9 months) and 15 months (95% CI 10.5-19.5 months), respectively. Toxicities included grade 3 and 4 leucopenia in 10 (30%), thrombocytopenia in 6 (18%), anemia in 2 (6%) and oral mucositis in 2 (6%). No grade 3 or 4 peripheral neuropathy, renal dysfunction, hepatic dysfunction, or nausea/vomiting was observed, and no treatment-related deaths occurred. Conclusion: The described gemcitabine plus cisplatin combination was found to be an active and tolerable salvage regimen in patients with taxane resistant metastatic breast cancer.

Original languageEnglish
Pages (from-to)269-274
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume59
Issue number2
DOIs
Publication statusPublished - 2007 Feb

Keywords

  • Cisplatin
  • Gemcitabine
  • Metastatic breast cancer
  • Taxane resistant

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this